CBX4 and osteosarcoma: Wang et al. found that by transcriptionally upregulating Runx2 via recruiting GCN5 to the Runx2 promoter, high CBX4 promoted metastasis in osteosarcoma and might be a potential therapeutic target in metastatic osteosarcoma [47].